Los Angeles, CA
Ketamine Therapy clinics in Los Angeles
Los Angeles has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. California is a leading market for IV ketamine clinics and compounded lozenge telehealth, with strong oversight by the Medical Board of California. Most Los Angeles clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Los Angeles only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Los Angeles, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Los Angeles sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Los Angeles ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Los Angeles PTSD Therapy Collective
- Ketamine Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
MD on staff
Bespoke Treatment
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
Felicity Mental Health Ketamine Therapy - Century City
- Ketamine Therapy
- Psychedelic Therapy
Westwood Minds Psychiatry & TMS
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Regulatory context
A note on California's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 803 (2023, vetoed) and SB 1012 (2024, stalled)
Proposed regulated therapeutic access to psilocybin, MDMA, mescaline, and DMT; Governor Newsom vetoed SB 58 (2023) citing lack of treatment guidelines. -
Local decriminalization resolutions
Oakland (2019), Santa Cruz (2020), Arcata, San Francisco, and Berkeley have passed non-binding resolutions deprioritizing enforcement of natural psychedelics; no legal therapeutic framework.
California enforces federal DEA scheduling. The Medical Board of California investigates prescriber misconduct, including ketamine diversion and inadequate patient monitoring. Several high-profile California ketamine-related deaths (including Matthew Perry's 2023 overdose) have intensified board scrutiny of clinic practices. DEA enforcement targets compounding, diversion, and Ryan Haight Act telehealth compliance.